July 28th 2025
Pooled data from early-phase trials suggest JSKN003 is tolerable and active in patients with heavily pretreated HER2-positive disease.
From Trial to Practice: Real-World Outcomes and The Evolving SERD Landscape
June 5th 2025Panelists discuss how real-world data from the San Antonio Breast Cancer Symposium demonstrated that elacestrant's performance in actual clinical practice even exceeded the promising results from the clinical trial.
Addition of Inavolisib Improves OS in PIK3CA-Mutant, HR+/HER2– Breast Cancer
May 23rd 2025The phase 3 INAVO120 trial showed that overall survival significantly improved with the addition of inavolisib to palbociclib and fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative, endocrine-resistant advanced breast cancer.
When Stable Disease Progresses: ESR1 Mutations at the Point Of Progression In Juliana’s Case
Panelists discuss how molecular testing and liquid biopsies are crucial for tracking estrogen receptor 1 (ESR1) mutations in patients with metastatic breast cancer, particularly as a mechanism of resistance to aromatase inhibitor treatment.